Financial & competing interests disclosure
RL Atmar has received grant support from Ligocyte Pharmaceuticals, Inc. MK Estes has a patent on the use of norovirus virus-like particles as a vaccine and serves as a consultant to Ligocyte Pharmaceuticals, Inc. Support for the manuscript was received in part from the NIH (P01 AI 57788, P30 DK56336), the United States Department of Agriculture (USDA 2011-68003-30395) and the John S. Dunn Research Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.